CoChat
Sign Up
Cited by 127Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsHeart Failure Treatment and Management

The benefits of GLP1 receptors in cardiovascular diseases

Open access
Ferhatbegović, Lamija, Mršić, Denis, Macić-Džanković, Amra·2023·Frontiers in Clinical Diabetes and Healthcare
DOI 10.3389/fcdhc.2023.1293926PMC PMC10739421
Open this paper in CoChat — free accountOpen PDF

Abstract

Glucagon like peptide-1 (GLP-1) receptor agonists are well established drugs for the treatment of type 2 diabetes (T2D). In addition to glycemic control, GLP-1 receptor agonists have beneficial other effects. They act by binding to GLP-1 receptors, which are widely distributed in the body, including cardiomyocytes and blood vessels. The aim of this article is to provide a comprehensive review of GLP-1 receptor agonists impact on cardiovascular outcomes and risk reduction. In the last decade, several cardiovascular outcomes trials (CVOT) have been conducted in order to explore cardiovascular benefit of GLP-1 receptor agonists. CVOTs primarily proved cardiovascular safety and tolerability of different GLP-1 receptor agonists, but also showed cardiovascular benefit of specific drugs. CVOTs have shown that GLP-1 receptor agonists reduce MACE in patients with T2D compared to placebo. In addition, they have positive impact on several cardiovascular risk factors such as obesity by promoting weight loss, blood pressure and blood lipid levels. Also, they stimulate the endothelium to produce nitric oxide, reduce oxidative stress, and have antiatherogenic and antiinflammatory effects. Studies have shown their positive impact on kidney outcomes in patients with T2D compared to placebo. The results of previous trials are encouraging in terms of multiple positive effects of GLP-1 receptor agonists. However, further research is needed to understand their full potential and all details of their mechanism of action, which will enable to expand the therapeutic indications and to determine their optimal use in clinical practice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcdhc.2023.1293926

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GLP-1 RAs exhibit beneficial effects on glycemic regulation, weight management, and cardiovascular outcomes.

    “These pharmacological agents exhibit beneficial effects on glycemic regulation, weight management, and cardiovascular outcomes, thereby establishing their essential roles in contemporary diabetes management [3-5].”

    From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [3]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. [1]Vaduganathan M Mensah GA Turco JV Fuster V Roth GA. The global burden of cardiovascular diseases and risk: A compass for future health. J Am Coll Cardiol (2022) 80(25): 2361–71. doi: 10.1016/j.jacc.2022.11.005 36368511 · DOI
  2. [2]Marx N Husain M Lehrke M Verma S Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation (2022) 146(24): 1882–94. doi: 10.1161/CIRCULATIONAHA.122.059595 36508493 · DOI
  3. [3]Sun F Wu S Guo S Yu K Yang Z Li L. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin practice (2015) 110(1): 26– 37. doi: 10.1016/j.diabres.2015.07.015 26358202 · DOI · Paper page
  4. [5]Klonoff DC Buse JB Nielsen LL Guan X Bowlus CL Holcombe JH. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res opinion (2008) 24(1): 275–86. doi: 10.1185/030079908X253870 18053320 · DOI · Paper page
  5. [6]Gaspari T Liu H Welungoda I Hu Y Widdop RE Knudsen LB. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diabetes Vasc Dis Res (2011) 8(2): 117–24. doi: 10.1177/1479164111404257 21562063 · DOI
  6. [7]Graaf C Donnelly D Wootten D Lau J Sexton PM Miller LJ. Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes. Pharmacol Rev (2016) 68(4): 954– 1013. doi: 10.1124/pr.115.011395 27630114 PMC5050443 · DOI · Paper page
  7. [13]Zhao X Wang M Wen Z Lu Z Cui L Fu C. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne) (2021) 12: 721135. doi: 10.3389/fendo.2021.721135 34497589 PMC8419463 · DOI · Paper page
  8. [14]Drucker DJ. The biology of incretin hormones. Cell Metab (2006) 3(3): 153–65. doi: 10.1016/j.cmet.2006.01.004 16517403 · DOI · Paper page
  9. [15]Kimani CN Reuter H Kotzé SH Muller CJF. Regeneration of pancreatic beta cells by modulation of molecular targets using plant-derived compounds: pharmacological mechanisms and clinical potential. Curr Issues Mol Biol (2023) 45(8): 6216–45. doi: 10.3390/cimb45080392 PMC10453321 37623211 · DOI
  10. [16]Steinert RE Beglinger C Langhans W. Intestinal GLP-1 and satiation: from man to rodents and back. Int J Obes (2016) 40(2): 198– 205. doi: 10.1038/ijo.2015.172 26315842 · DOI
  11. [17]Deacon CF Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin pharmacother (2013) 14(15): 2047–58. doi: 10.1517/14656566.2013.824966 23919507 · DOI
  12. [18]Nauck MA Quast DR Wefers J Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab (2021) 46: 101102. doi: 10.1016/j.molmet.2020.101102 33068776 PMC8085572 · DOI · Paper page
  13. [19]Yoo BK Triller DM Yoo DJ. Exenatide: a new option for the treatment of type 2 diabetes. Ann Pharmacother (2006) 40(10): 1777–84. doi: 10.1345/aph.1H060 16985091 · DOI
  14. [20]Seo YG. Side effects associated with liraglutide treatment for obesity as well as diabetes. J Obes Metab syndrome (2021) 30(1): 12–9. doi: 10.7570/jomes20059 PMC8017323 33071241 · DOI
  15. [21]Leon N LaCoursiere R Yarosh D Patel RS. Lixisenatide (Adlyxin): A once-daily incretin mimetic injection for type-2 diabetes. P T peer-reviewed J formulary management (2017) 42(11): 676– 711. PMC5642155 29089722
  16. [22]Wysham C Grimm M Chen S. Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes Obes Metab (2013) 15(10): 871–81. doi: 10.1111/dom.12084 23425609 · DOI
  17. [23]Arslanian SA Hannon T Zeitler P Chao LC Boucher-Berry C Barrientos-Pérez M. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med (2022) 387(5): 433–43. doi: 10.1056/NEJMoa2204601 35658022 · DOI
  18. [25]Hughes S Neumiller JJ. Oral semaglutide. Clin Diabetes (2020) 38(1): 109–11. doi: 10.2337/cd19-0079 PMC6969659 31975761 · DOI
  19. [26]Nauck MA Stewart MW Perkins C Jones-Leone A Yang F Perry C. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia (2016) 59(2): 266–74. doi: 10.1007/s00125-015-3795-1 PMC4705137 26577795 · DOI
  20. [27]Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care (2011) 34 Suppl 2(Suppl 2): S279–84. doi: 10.2337/dc11-s231 PMC3632193 21525469 · DOI · Paper page
  21. [28]Gallwitz B. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp Pharmacol (2011) 203: 53– 74. doi: 10.1007/978-3-642-17214-4_3 21484567 · DOI
  22. [29]Okerson T Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther (2012) 30(3): e146–55. doi: 10.1111/j.1755-5922.2010.00256.x PMC3488299 21167014 · DOI
  23. [31]Htike ZZ Zaccardi F Papamargaritis D Webb DR Khunti K Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab (2017) 19(4): 524–36. doi: 10.1111/dom.12849 27981757 · DOI
  24. [32]Sim R Chong CW Loganadan NK Fong AYY Navaravong L Hussein Z. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. Diabetic Med (2022) 39(3): e14780. doi: 10.1111/dme.14780 34962662 · DOI
  25. [33]Tran S Retnakaran R Zinman B Kramer CK. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes Obes Metab (2018) 20 Suppl 1: 68– 76. doi: 10.1111/dom.13137 29364587 · DOI
  26. [36]Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev (2007) 87(4): 1409–39. doi: 10.1152/physrev.00034.2006 17928588 · DOI · Paper page
  27. [40]Holman RR Bethel MA Mentz RJ Thompson VP Lokhnygina Y Buse JB. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med (2017) 377(13): 1228–39. doi: 10.1056/NEJMoa1612917 PMC9792409 28910237 · DOI · Paper page
  28. [41]Hernandez AF Green JB Janmohamed S D'Agostino RB Granger CB Jones NP. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet (London England) (2018) 392(10157): 1519–29. doi: 10.1016/S0140-6736(18)32261-X 30291013 · DOI · Paper page
  29. [42]Gerstein HC Colhoun HM Dagenais GR Diaz R Lakshmanan M Pais P. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London England) (2019) 394(10193): 121–30. doi: 10.1016/S0140-6736(19)31149-3 31189511 · DOI · Paper page
  30. [43]Husain M Birkenfeld AL Donsmark M Dungan K Eliaschewitz FG Franco DR. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med (2019) 381(9): 841–51. doi: 10.1056/NEJMoa1901118 31185157 · DOI · Paper page
  31. [44]Gerstein HC Sattar N Rosenstock J Ramasundarahettige C Pratley R Lopes RD. Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes. N Engl J Med (2021) 385(10): 896– 907. doi: 10.1056/NEJMoa2108269 34215025 · DOI · Paper page
  32. [47]Frias JP Bonora E Nevarez Ruiz L Li YG Yu Z Milicevic Z. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care (2021) 44(3): 765–73. doi: 10.2337/dc20-1473 PMC7896253 33397768 · DOI · Paper page
  33. [48]Holman RR Paul SK Bethel MA Matthews DR Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 359(15): 1577–89. doi: 10.1056/NEJMoa0806470 18784090 · DOI · Paper page
  34. [53]Nyström T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Hormone Metab. Res. = Hormon- und Stoffwechselforschung = Hormones metabolisme (2008) 40(9): 593– 606. doi: 10.1055/s-0028-1082326 18792870 · DOI
  35. [54]Puglisi S Rossini A Poli R Dughera F Pia A Terzolo M. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol (Lausanne) (2021) 12: 738848. doi: 10.3389/fendo.2021.738848 34745006 PMC8567993 · DOI · Paper page
  36. [55]Yu JH Park SY Lee DY Kim NH Seo JA. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Res Clin practice (2022) 41(2): 136–49. doi: 10.23876/j.krcp.22.001 PMC8995488 35391537 · DOI
  37. [57]Petrovic A Igrec D Rozac K Bojanic K Kuna L Kolaric TO. The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD. Curr Issues Mol Biol (2023) 45(6): 4544–56. doi: 10.3390/cimb45060288 PMC10296833 37367037 · DOI · Paper page
  38. [58]Bułdak Ł Machnik G Bułdak RJ Łabuzek K Bołdys A Belowski D. Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner. Pharmacol Rep (2016) 68(2): 329–37. doi: 10.1016/j.pharep.2015.10.008 26922535 · DOI
  39. [59]Arakawa M Mita T Azuma K Ebato C Goto H Nomiyama T. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes (2010) 59(4): 1030–7. doi: 10.2337/db09-1694 PMC2844811 20068138 · DOI · Paper page
  40. [61]Savarese G Becher PM Lund LH Seferovic P Rosano GMC Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res (2023) 118(17): 3272–87. doi: 10.1093/cvr/cvac013 35150240 · DOI
  41. [63]Jorsal A Kistorp C Holmager P Tougaard RS Nielsen R Hänselmann A. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail (2017) 19(1): 69– 77. doi: 10.1002/ejhf.657 27790809 · DOI · Paper page
  42. [68]Xie Y Bowe B Xian H Loux T McGill JB Al-Aly Z. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol (2023) 11(9): 644–56. doi: 10.1016/S2213-8587(23)00171-7 37499675 · DOI · Paper page
  43. [69]Giugliano D Longo M Signoriello S Maiorino MI Solerte B Chiodini P. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol (2022) 21(1): 42. doi: 10.1186/s12933-022-01474-z 35296336 PMC8925229 · DOI · Paper page

Cited by

Sorted by citations

Authors
Ferhatbegović, L., Mršić, D., & Macić-Džanković, A.
Affiliations
  • University of Zenica (BA)
  • University Clinical Center Tuzla (BA)
  • Univerzitet Vitez (BA)
Corresponding author
Ferhatbegović, Lamija
ORCID
Venue
Frontiers in Clinical Diabetes and Healthcare
Publisher
Frontiers Media SA
Published
2023-12-08
Volume
4
Pages
1293926-1293926
ISSN
2673-6616 (ISSN-L)
DOI
10.3389/fcdhc.2023.1293926
PMC
PMC10739421
OpenAlex
W4389480516
Cited by
127
References
26
Citations by year
2026: 38 · 2025: 63 · 2024: 26
FWCI
4.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Clinical Diabetes and Healthcare (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
GLP-1 receptor agonists, cardiovascular outcomes, type 2 diabetes, major adverse cardiovascular events, cardiovascular risk reduction, obesity, blood pressure, serum lipids, nitric oxide, oxidative stress, anti-inflammatory activity, antiatherogenic effects, renal outcomes, endothelium

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review